Cassava Sciences Inc
NASDAQ:SAVA

Watchlist Manager
Cassava Sciences Inc Logo
Cassava Sciences Inc
NASDAQ:SAVA
Watchlist
Price: 2.0446 USD -0.26%
Market Cap: 98.8m USD

Relative Value

There is not enough data to reliably calculate the relative value of SAVA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SAVA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-18.3
Industry
21.5
Forward
-5
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-16.2
Industry
16.6
vs History
vs Industry
Median 3Y
-11.8
Median 5Y
-15
Industry
24
vs History
93
vs Industry
70
Median 3Y
4.9
Median 5Y
6
Industry
2.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
vs History
4
vs Industry
56
Median 3Y
-8.5
Median 5Y
-10.3
Industry
12.8
vs History
4
vs Industry
53
Median 3Y
-8.3
Median 5Y
-10.1
Industry
16.2
Forward
0.5
vs History
4
vs Industry
57
Median 3Y
-10.4
Median 5Y
-13.6
Industry
14.9
vs History
4
vs Industry
43
Median 3Y
-10.1
Median 5Y
-11.7
Industry
17.7
vs History
vs Industry
7
Median 3Y
34.1
Median 5Y
35.6
Industry
1.9

Multiples Across Competitors

SAVA Competitors Multiples
Cassava Sciences Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cassava Sciences Inc
NASDAQ:SAVA
98.8m USD 0 -1.4 0.1 0.1
US
Eli Lilly and Co
NYSE:LLY
769.2B USD 15.7 69.2 37.1 40.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.6B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.3 21.1 14.6 16.7
CH
Roche Holding AG
SIX:ROG
210B CHF 3.5 25.3 9.5 11.1
CH
Novartis AG
SIX:NOVN
189B CHF 4.4 18.1 10.7 14.3
UK
AstraZeneca PLC
LSE:AZN
167.7B GBP 4.1 29.3 131.2 197.8
US
Merck & Co Inc
NYSE:MRK
203.3B USD 3.2 11.6 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
138.7B USD 2.2 17.6 7.5 10.6
P/E Multiple
Earnings Growth PEG
US
Cassava Sciences Inc
NASDAQ:SAVA
Average P/E: 26.2
Negative Multiple: -1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
69.2
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.1
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.3
32%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.6
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cassava Sciences Inc
NASDAQ:SAVA
Average EV/EBITDA: 394.5
0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.7
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.2
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Cassava Sciences Inc
NASDAQ:SAVA
Average EV/EBIT: 1 697.8
0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.6
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
16.7
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.9
CH
Novartis AG
SIX:NOVN
14.3
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.8
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
10%
1.1